← All trials
NCT05700695
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 17, 2023
- Primary completion
- Apr 25, 2025
- Completion date
- Apr 25, 2025
- First posted
- Jan 26, 2023
- Last posted
- Jan 26, 2023
- Enrollment
- 246
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Postgraduate Institute of Medical Education and ResearchLead sponsor
- All India Institute of Medical SciencesCollaborator
- Amrita Institute of Medical SciencesCollaborator
- Asian Institute of GastroenterologyCollaborator
- Postgraduate Institute of Medical Education and ResearchReponsible party - principal investigator
- Postgraduate Institute of Medical Education and ResearchSponsor investigator
- Kalinga Institute of Medical Sciences, BhubaneswarCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.